Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
Type:
Grant
Filed:
April 13, 2018
Date of Patent:
September 20, 2022
Assignee:
SENTI BIOSCIENCES, INC.
Inventors:
Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang
Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
Type:
Grant
Filed:
March 31, 2021
Date of Patent:
August 23, 2022
Assignee:
SENTI BIOSCIENCES, INC.
Inventors:
Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang, Daniel Frimannsson
Abstract: Described herein are engineered fusion proteins comprising a variant protease (e.g., an HCV NS3 protease) fused to a polypeptide of interest and a cognate protease cleavage site. The cleavability of the cognate protease cleavage site enables the controllability of one or more functions of the polypeptide of interest. Additionally disclosed are methods for generating engineered fusion proteins as well as their therapeutic use.
Type:
Application
Filed:
January 24, 2020
Publication date:
March 24, 2022
Applicants:
Senti Biosciences, Inc., Senti Biosciences, Inc.
Inventors:
Daniel Frimannsson, Philip Janmin Lee, Timothy Kuan-Ta Lu, Russell Morrison Gordley
Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
Type:
Grant
Filed:
October 17, 2019
Date of Patent:
May 4, 2021
Assignee:
SENTI BIOSCIENCES, INC.
Inventors:
Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang, Daniel Frimannsson
Abstract: Provided herein, in some embodiments, are methods, compositions, systems and kits that enable spatiotemporal regulation of nucleic acid expression in engineered cells.
© 2025 Justia
